Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$24.44
+0.43 (+1.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $28.7M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.5B
P/E
53.1x
↑EV/EBITDA
20.5x
↑ROE
4.8%
↑Gross Margin
49.5%
↑Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.2%
FCF CAGR
+11.1%
FCF margin
5.9%
FCF / Net income
1.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $900.8M · net income $51.9M · FCF $53.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $900.8M | $900.8M | $812.1M | $785.2M | $691.6M |
| Net Income | $51.9M | $51.9M | $37.5M | $86.3M | $67.8M |
| EBITDA | $114.5M | $114.5M | $95.8M | $136.2M | $112.9M |
| EPS | 0.50 | 0.50 | 0.37 | 0.84 | 0.80 |
| Gross Margin | 49.5% | 49.5% | 50.8% | 51.3% | 50.2% |
| Operating Margin | 6.8% | 6.8% | 6.2% | 11.7% | 11.8% |
| Net Margin | 5.8% | 5.8% | 4.6% | 11.0% | 9.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.19 | 0.00 | — |
| Current Ratio | 2.36 | 2.36 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $53.2M | $53.2M | $28.7M | $-50.0M | $38.8M |
| Returns | |||||
| ROE | 4.8% | 4.8% | 3.5% | 7.8% | 5.9% |
| Valuation | |||||
| P/E | 53.13 | 53.13 | 60.77 | 32.71 | 34.52 |
| EV/EBITDA | 20.47 | 20.47 | 21.99 | 19.01 | 17.70 |
| P/B | 2.35 | 2.35 | 2.15 | 2.56 | 2.03 |
| Growth & Yield | |||||
| Revenue Growth | 10.9% | 10.9% | 3.4% | 13.5% | — |
| EPS Growth | 35.7% | 35.7% | -55.7% | 4.4% | — |
| Dividend Yield | 4.1% | 4.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
62.6%
EPS terminal req.
$2.17
Spread vs growth
-26.9%
5Y implied EPS CAGR
39.1%
EPS terminal req.
$2.62
Spread vs growth
-3.4%
10Y implied EPS CAGR
23.7%
EPS terminal req.
$4.23
Spread vs growth
12.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.4%
Start / end P/E
69.4x → 49.7x
EPS bridge
0.37 → 0.50
Residual
-10.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.